Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

489
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
489
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

419
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
419
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

25
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
25
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

21
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
21
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

311
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
311
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

31
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
31

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Controlling and self assembling of monodisperse platinum nanocubes as efficient methanol oxidation electrocatalysts.

Chemical communications (Cambridge, England)·2015
Same author

Pd-nanoparticle-supported, PDDA-functionalized graphene as a promising catalyst for alcohol oxidation.

Chemistry, an Asian journal·2015
Same author

[Efficacy and safety of Longjintonglin Capsule for the treatment of type III prostatitis].

Zhonghua nan ke xue = National journal of andrology·2015
Same author

Prognostic factors for conjunctival melanoma: a study in ethnic Chinese patients.

The British journal of ophthalmology·2015
Same author

Twist1 correlates with poor differentiation and progression in gastric adenocarcinoma via elevation of FGFR2 expression.

World journal of gastroenterology·2015
Same author

[Genetic polymorphisms of PDGFR associated with thrombocytopenia in Chinese patients with clear-cell metastatic renal cell carcinoma treated with sunitinib].

Zhonghua yi xue za zhi·2014
Same journal

Splenic Angiosarcoma Misdiagnosed as PrimaryMyelofibrosis: Report of Two Cases and a Literature Review.

Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae·2026
Same journal

Anesthetic Management for Epicardial Pacemaker Implantation in An Adult Patient With Uncorrected Functional Single Ventricle:A Case Report.

Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae·2026
Same journal

Magnetic Resonance Imaging Combined With Ultrasonography for Early Diagnosis of Complete Hydatidiform Mole With Coexisting Fetus: Report of One Case.

Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae·2026
Same journal

Prospects for China's Pharmaceutical Industry Development During the 15th Five-Year Plan Period.

Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae·2026
Same journal

[Comparison of Imaging Efficacy and Patient Tolerability Between a Novel Cellulose-Based anda Conventional Starch-Based Oral Contrast Agent: A Prospective Randomized Controlled Trial].

Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae·2026
Same journal

[Application Value of Super-Resolution Ultrasound Imaging in the Diagnosisof American College of Radiology Thyroid Imaging Reporting and Data System Category 4 and 5 Thyroid Nodules].

Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae·2026
See all related articles

Related Experiment Video

Updated: Aug 29, 2025

Implantation of Combined Telemetric ECG and Blood Pressure Transmitters to Determine Spontaneous Baroreflex Sensitivity in Conscious Mice
09:56

Implantation of Combined Telemetric ECG and Blood Pressure Transmitters to Determine Spontaneous Baroreflex Sensitivity in Conscious Mice

Published on: February 14, 2021

5.2K

[Baroreflex ActivationTherapy for Heart Failure].

Yi Xu1, Yue-Jin Yang2, Jun Guo1

  • 1Department of Cardiology,The First Affiliated Hospital of Jinan University,Guangzhou 510630,China.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae
|September 6, 2022
PubMed
Summary
This summary is machine-generated.

Baroreflex activation therapy (BAT) shows promise for treating heart failure (HF) by improving autonomic regulation. This novel therapy stimulates the carotid sinuses, offering a new approach to managing HF prognosis.

Keywords:
autonomic nervous systembaroreflex activation therapydevice-based therapyheart failure

More Related Videos

Breathing-controlled Electrical Stimulation BreEStim for Management of Neuropathic Pain and Spasticity
11:34

Breathing-controlled Electrical Stimulation BreEStim for Management of Neuropathic Pain and Spasticity

Published on: January 10, 2013

23.2K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.6K

Related Experiment Videos

Last Updated: Aug 29, 2025

Implantation of Combined Telemetric ECG and Blood Pressure Transmitters to Determine Spontaneous Baroreflex Sensitivity in Conscious Mice
09:56

Implantation of Combined Telemetric ECG and Blood Pressure Transmitters to Determine Spontaneous Baroreflex Sensitivity in Conscious Mice

Published on: February 14, 2021

5.2K
Breathing-controlled Electrical Stimulation BreEStim for Management of Neuropathic Pain and Spasticity
11:34

Breathing-controlled Electrical Stimulation BreEStim for Management of Neuropathic Pain and Spasticity

Published on: January 10, 2013

23.2K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.6K

Area of Science:

  • Cardiology
  • Autonomic Neuroscience
  • Medical Devices

Background:

  • Heart failure (HF) represents the advanced stage of various cardiovascular conditions.
  • Dysfunctional autonomic regulation and an imbalance between sympathetic and parasympathetic nervous system activity are critical drivers of HF progression.
  • Current therapeutic strategies for HF often struggle to address the underlying autonomic dysfunction.

Purpose of the Study:

  • To review and synthesize the latest research on Baroreflex Activation Therapy (BAT) for heart failure.
  • To evaluate the efficacy of BAT in improving HF outcomes and prognosis.
  • To provide evidence supporting further investigation into BAT as a treatment modality for HF.

Main Methods:

  • Systematic review of recent clinical studies and trials investigating BAT in HF patients.
  • Analysis of data on autonomic function, cardiac parameters, and clinical outcomes following BAT.
  • Evaluation of the safety and tolerability profile of BAT.

Main Results:

  • BAT demonstrates significant efficacy in managing heart failure.
  • Studies indicate improvements in autonomic regulation and sympathetic-parasympathetic balance with BAT.
  • BAT has shown positive effects on HF prognosis and patient outcomes.

Conclusions:

  • Baroreflex activation therapy (BAT) is a promising device-based treatment for heart failure.
  • BAT effectively modulates autonomic function, addressing a key pathophysiological mechanism in HF.
  • Further research is warranted to establish BAT as a standard therapeutic option for heart failure management.